Trial Profile
Impact of switching from once-weekly GLP1receptor agonist to once-weekly DPP4inhibitor(Omaligliptin)therapy on glycemic control parameters in type 2 diabetes patients undergoing hemodialysis.
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2017
Price :
$35
*
At a glance
- Drugs Omarigliptin (Primary) ; Dulaglutide
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms DO study
- 06 Nov 2017 New trial record